Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Xiaomei Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5914-4373; OpenAlex author ID A5080112385. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 5 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 4 papers · 2025: 5 papers

Papers 22

  1. OSBPL10-CNBP axis mediates hypoxia-induced pancreatic cancer development. Co-author DOI 10.1002/biof.2124↗
  2. TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113060↗
  3. The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer. Co-author DOI 10.1016/j.jare.2024.01.014↗
  4. Retraction Note: Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer. Co-author DOI 10.1038/s41388-025-03629-0↗
  5. TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC. Co-author DOI 10.1186/s13578-025-01350-9↗
  6. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  7. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. Co-author DOI 10.1007/s13402-023-00907-5↗
  8. KLK10/LIPH/PARD6B/SLC52A3 are promising molecular biomarkers for the prognosis of pancreatic cancer through a ceRNA network. Co-author DOI 10.1016/j.heliyon.2024.e24287↗
  9. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  10. A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresi… Co-author DOI 10.1038/s41421-023-00592-6↗
  11. Hypoxia-induced long non-coding RNA LINC00460 promotes p53 mediated proliferation and metastasis of pancreatic cancer by regulating the miR-4689/UBE2V1 axis an… Co-author DOI 10.7150/ijms.87833↗
  12. Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.682261↗
  13. Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer. Co-author DOI 10.1038/s41388-019-0930-3↗
  14. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914557116↗
  15. Comparison of Radical Antegrade Modular Pancreatosplenectomy with Standard Retrograde Pancreatosplenectomy for Left-Sided Pancreatic Cancer: A Meta-Analysis an… Co-author DOI 10.12659/msm.914540↗
  16. PRPF40A as a potential diagnostic and prognostic marker is upregulated in pancreatic cancer tissues and cell lines: an integrated bioinformatics data analysis. Co-author DOI 10.2147/ott.s206039↗
  17. INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT. Co-author DOI 10.2147/ott.s223221↗
  18. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0965-3↗
  19. MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. First author DOI 10.1016/j.bbrc.2016.12.167↗
  20. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  21. Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance. Co-author DOI 10.3892/or.2017.6026↗
  22. mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.7375↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 9 shared papers, 2017–2024 · strength 1.05
  2. Shuyu Zhai · 7 shared papers, 2019–2024 · strength 0.94
  3. Xiaxing Deng · 6 shared papers, 2018–2025 · strength 0.92
  4. Yizhi Cao · 5 shared papers, 2023–2025 · strength 0.91
  5. Ronghao Zhang · 4 shared papers, 2023–2025 · strength 0.75
  6. Xiaxing Deng · 7 shared papers, 2016–2024 · strength 0.73
  7. Xinjing Wang · 6 shared papers, 2016–2025 · strength 0.70
  8. Weishen Wang · 4 shared papers, 2021–2024 · strength 0.62
  9. Chenlei Wen · 7 shared papers, 2016–2024 · strength 0.57
  10. Da Fu · 3 shared papers, 2023–2025 · strength 0.54
  11. Chenghong Peng · 6 shared papers, 2016–2024 · strength 0.51
  12. Lingxi Jiang · 3 shared papers, 2024–2025 · strength 0.50
  13. Pengyi Liu · 3 shared papers, 2023–2024 · strength 0.49
  14. Xiongxiong Lu · 6 shared papers, 2016–2021 · strength 0.46
  15. Yishu Huang · 2 shared papers, 2023–2025 · strength 0.45
  16. Yunfeng Wang · 2 shared papers, 2025 · strength 0.42
  17. Hao Qian · 4 shared papers, 2019–2021 · strength 0.40
  18. Yu‐Shui Ma · 2 shared papers, 2024–2025 · strength 0.39
  19. Meilin Xue · 2 shared papers, 2024–2025 · strength 0.37
  20. Jiaxin Luo · 2 shared papers, 2024–2025 · strength 0.37
  21. Yihao Liu · 2 shared papers, 2024 · strength 0.34
  22. Youwei Zhu · 2 shared papers, 2024 · strength 0.34
  23. Yang Liu · 2 shared papers, 2024 · strength 0.34
  24. Ji Zhang · 2 shared papers, 2019–2025 · strength 0.34
  25. Haiwei Wang · 2 shared papers, 2019–2025 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.